Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: A data collection from Plasma Protein Therapeutics Association member companies

Transfusion

Volumn 51, Issue 7, 2011, Pages 1412-1430

  Dichtelmüller, Herbert O ^{a,b,c,d,e,f,g,h}   Biesert, Lothar ^{a,b,c,d,e,f,g,h}   Fabbrizzi, Fabrizio ^{a,b,c,d,e,f,g,h}   Falbo, Anna ^{a,b,c,d,e,f,g,h}   Flechsig, Eckhard ^{a,b,c,d,e,f,g,h}   Gröner, Albrecht ^{a,b,c,d,e,f,g,h}   Von Hoegen, Ilka ^{a,b,c,d,e,f,g}   Kempf, Christoph ^{a,b,c,d,e,f,g,h}   Kreil, Thomas R ^{a,b,c,d,e,f,g,h}   Lee, Douglas C ^{a,b,c,d,e,f,g,h}   Pölsler, Gerhard ^{a,b,c,d,e,f,g,h}   Roth, Nathan J ^{a,b,c,d,e,f,g,h}  

^a BIOTEST AG   (Germany)

^b Octapharma   (Germany)

^c Kedrion ^*  (Italy)

^d CSL BEHRING GMBH   (Germany)

^e PPTA   (Belgium)

^f CSL Behring   (Switzerland)

^g BAXTER BIOSCIENCE   (Austria)

^h Talecris Biotherapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALCOHOL; IMMUNOGLOBULIN;

ARTICLE; CENTRIFUGATION; CONCENTRATION (PARAMETERS); FILTRATION; FRACTIONATION; NONHUMAN; PH MEASUREMENT; TEMPERATURE MEASUREMENT; VIRAL CLEARANCE; VIRAL PHENOMENA AND FUNCTIONS; VIRUS INACTIVATION; VIRUS PARTITIONING; VIRUS PURIFICATION;

CHEMICAL FRACTIONATION; DATA COLLECTION; ETHANOL; HUMANS; IMMUNOGLOBULINS; SAFETY; SERUM ALBUMIN; VIRUS INACTIVATION;

EID: 79960181058     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.03003.x     Document Type: Article

References (26)

1. Cohn EJ, Strong LE, Hughes WL Jr, Mulford DJ, Aschworth JN, Melin M, Taylor HL,. Preparations and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946; 68: 459-75.
2. Oncley JL, Melin M, Richert DA, Cameron JW, Gross PM,. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and β-lipoprotein into subfractions of human plasma. J Am Chem Soc 1949; 71: 541-50.
3. Kistler P, Nitschmann H,. Large Scale production of human plasma fractions. Vox Sang 1962; 7: 414-24.
4. Friedli H, Mauerhofer M, Faes A, Kistler P,. Studies on new process procedures in plasma fractionation on an industrial scale. III. Removal of precipitates by filtration through a horizontal leaf filter with centrifugal cleaning (Funda filter) as an alternative to tubular-bowl centrifuges. Vox Sang 1976; 31: 289-95.
5. Yei S, Yu MW, Tankersley DL,. Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma. Transfusion 1992; 32: 824-8. (Pubitemid 23001626)
6. Wells MA, Wittek AE, Epstein JS, Marcus-Sekura C, Daniel S, Tankersley DL, Preston MS, Quinnan GV Jr,. Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma. Transfusion 1986; 26: 210-3. (Pubitemid 16139680)
7. Henin Y, Marechal V, Barre-Sinoussi F, Chermann JC, Morgenthaler JJ,. Inactivation and partition of human immunodeficiency virus during Kistler and Nitschmann fractionation of human blood plasma. Vox Sang 1988; 54: 48-83.
8. European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses; CPMP/BWP/268/95. 1996.
9. European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Note for guidance on plasma-derived medicinal products; CPMP/BWP/269/95, rev. 3. 2001.
10. ICH Steering Committee. ICH harmonised tripartite guideline: virus safety of biotechnology products derived from cell lines of human or animal origin Q5A. 1997.
11. Boschetti N, Stucki M, Späth PH, Kempf C,. Virus safety of intravenous immunoglobulin. Clin Rev Allerg Immunol 2005; 29: 333-44.
12. Biesert L,. Virus validation studies of immunoglobulin preparations. Clin Exp Rheumatol 1996; 14 Suppl: s47-52. (Pubitemid 26270578)
13. Trejo SR, Hotta JA, Lebing W, Stenland C, Storms RE, Lee DC, Li H, Petteway S, Remington KM,. Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. Vox Sang 2003; 84: 176-87. (Pubitemid 36514174)
14. Stucki M, Schäfer W, Hostettler T, Käsermann F, Nowak T, Gröner A, Sabald A, Kempf C,. Pathogen safety of a new 20% liquid immunoglobulin product. J Aller Clin Immunol 2009; 123: s89.
15. Kempf C, Stucki M, Boschetti N,. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins. Biologicals 2007; 35: 35-42. (Pubitemid 46282490)
16. Mann H, Whitney D,. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 1947; 18: 50-60.
17. Kaerber G,. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Pathol Pharmakol 1931; 162: 480.
18. Morgenthaler JJ, Omar A,. Partitioning and inactivation of viruses during isolation of albumin and immunoglobulins by cold ethanol fractionation. In:, Brown F, editor. Virological safety aspects of plasma derivatives. Basel: Karger. Dev Biol Stand 1993; 81: 185-90.
19. European Medicines Agency. Committee for Medicinal Products for Human Use. Draft. Guideline on plasma-derived medicinal products; CPMP/BWP/269/95 rev.4. 19 Febr 2009.
20. Gellis SS, Neefe JR, Stokes J, Strong LE, Janeway CA, Scatchard G,. Chemical clinical and immunological studies on the products of human plasma fractionation. XXXVI. Inactivation of the virus of homologous serum hepatitis in solutions of normal human serum albumin by means of heat. J Clin Invest 1948; 27: 239-44.
21. Horowitz B, Prince AM, Hamman J, Watklevicz C,. Viral safety of solvent/detergent treated blood products. In:, Brown F, editor. Virological safety aspects of plasma derivatives. Basel: Karger. Dev Biol Stand 1993; 81: 147-61.
22. Horowitz B, Wiebe ME, Lippin A, Stryker MHG,. Inactivation of viruses in labile blood products I. Disruption of lipid enveloped viruses by tri (n-butyl) phosphate/detergent combinations. Transfusion 1985; 25: 516-22. (Pubitemid 16174459)
23. Dichtelmüller HO, Biesert L, Fabbrizzi F, Gajardo R, Gröner A, von Hoegen I, Jorquera JI, Kempf C, Kreil TR, Pifat D, Osheroff W, Poelsler G,. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from PPTA member companies. Transfusion 2009; 49: 1931-43.
24. Lundblad JL, Seng RL,. Inactivation of lipid enveloped viruses in proteins by caprylate. Vox Sang 1991; 60: 75-81.
25. Dichtelmüller H, Rudnick D, Kloft M,. Inactivation of lipid enveloped viruses by octanoic acid treatment of immunoglobulin solution. Biologicals 2002; 30: 135-42. (Pubitemid 36268641)
26. Xie YW, Chan PK, Szeto CK, Kwok SY, Chu IM, Chu SS, Cheung JL, Wong SW, Ali MB, Wong BL,. Clearance of dengue virus in the plasma-derived therapeutic proteins. Transfusion 2009; 48: 1342-7.